In the cerebral circulation, endothelial dysfunction caused by decreased biological activity and/or biosynthesis of nitric oxide (NO) is principal mechanism responsible for initiation and progression of vascular disease. Epidemiological studies established strong association between vascular disorders and incident Alzheimer's disease (AD). However, the molecular mechanisms linking cerebrovascular disease and AD are unknown. Our recently published findings (Circulation Research, 107:1498-1502, 2010) and preliminary experiments identified previously unrecognized role of endothelial NO in modulation of amyloid precursor protein (APP), ?- secretase (BACE1) and amyloid-? peptide (A?). Pharmacological or genetic inactivation of endothelial nitric oxide synthase (eNOS) causes up-regulation of APP and BACE1, leading to increased production of A?. Moreover, we have preliminary evidence suggesting that activation of peroxisome proliferation-activated receptor-? (PPAR?) exerts beneficial effect on endothelial function by enhancing production of NO. Moreover, activation of PPAR? prevents amyloidogenic processing of APP. Based on these finings we formulated following central hypothesis: impairment of endothelial function in the cerebral circulation plays a critical role in initiation and progression of AD pathology. To test this hypothesis we propose three specific aims: 1) Determine the molecular mechanisms that underline the effects of eNOS/cGMP signaling on expression and processing of APP, 2) Define the role of PPAR? in cerebrovascular endothelial function and processing of APP and 3) Assess the role of eNOS/cGMP signaling in initiation and progression of AD pathology. Cultured human brain microvascular endothelial cells will be used to study signal transduction pathways responsible for NO effects on generation of A?. These studies will be followed by in vivo testing of the proposed hypothesis in genetically modified mice including eNOS, nNOS-, and iNOS-deficient mice, ?1 or ?1 isoform of soluble guanylate cyclase-deficient mice, and endothelial specific PPAR?-defcient mice. To determine the role of eNOS in onset and progression of AD we propose to cross eNOS-deficient (eNOS-/-) mice with murine models of AD. Created AD mice lacking eNOS will provide new and unique models of AD relevant to study contribution of endothelial dysfunction to development of amyloid pathology. Functional, biochemical and morphological analyses will be preformed on microvessels and neuronal tissue. We anticipate that successful completion of the proposed studies will define the role of eNOS/cGMP signaling and activation of PPAR? in production of A?. We expect the results of our proposed studies will establish cerebrovascular endothelium as a critical target in the prevention of AD thereby directing and concentrating therapeutic focus on the cerebral circulation.

Public Health Relevance

Dysfunction of endothelial cells (inner lining of the brain arteries) is believed to play an important role in initiation and progression of Alzheimer's disease. The long-term goal of the studies proposed in this application is to determine the mechanisms underlying alterations in function of brain blood vessels that could contribute to development of Alzheimer's disease. We propose to create new experimental models of Alzheimer's disease which will be very useful in studies designed to determine contribution of diseased arteries to development of the cognitive impairment. In addition, these models will be employed in testing novel therapies for prevention and treatment of Alzheimer's disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL111062-02
Application #
8403744
Study Section
Vascular Cell and Molecular Biology Study Section (VCMB)
Program Officer
Reid, Diane M
Project Start
2012-01-01
Project End
2016-12-31
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
2
Fiscal Year
2013
Total Cost
$429,912
Indirect Cost
$153,286
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Sun, Ruohan; He, Tongrong; Pan, Yujun et al. (2018) Effects of senescence and angiotensin II on expression and processing of amyloid precursor protein in human cerebral microvascular endothelial cells. Aging (Albany NY) 10:100-114
d'Uscio, Livius V; He, Tongrong; Katusic, Zvonimir S (2017) Expression and Processing of Amyloid Precursor Protein in Vascular Endothelium. Physiology (Bethesda) 32:20-32
Austin, Susan A; Katusic, Zvonimir S (2016) Loss of Endothelial Nitric Oxide Synthase Promotes p25 Generation and Tau Phosphorylation in a Murine Model of Alzheimer's Disease. Circ Res 119:1128-1134
Santhanam, Anantha Vijay R; d'Uscio, Livius V; He, Tongrong et al. (2015) Uncoupling of endothelial nitric oxide synthase in cerebral vasculature of Tg2576 mice. J Neurochem 134:1129-38
Austin, Susan A; Santhanam, Anantha Vijay R; d'Uscio, Livius V et al. (2015) Regional Heterogeneity of Cerebral Microvessels and Brain Susceptibility to Oxidative Stress. PLoS One 10:e0144062
Santhanam, Anantha Vijay R; d'Uscio, Livius V; Katusic, Zvonimir S (2015) Characterization of cerebral microvasculature in transgenic mice with endothelium targeted over-expression of GTP-cyclohydrolase I. Brain Res 1625:198-205
Katusic, Zvonimir S; Austin, Susan A (2014) Endothelial nitric oxide: protector of a healthy mind. Eur Heart J 35:888-94
d'Uscio, Livius V; He, Tongrong; Santhanam, Anantha Vijay R et al. (2014) Mechanisms of vascular dysfunction in mice with endothelium-specific deletion of the PPAR-? gene. Am J Physiol Heart Circ Physiol 306:H1001-10
Santhanam, Anantha Vijay R; d'Uscio, Livius V; Katusic, Zvonimir S (2014) Erythropoietin increases bioavailability of tetrahydrobiopterin and protects cerebral microvasculature against oxidative stress induced by eNOS uncoupling. J Neurochem 131:521-9
d?Uscio, Livius V; Santhanam, Anantha V R; Katusic, Zvonimir S (2014) Erythropoietin prevents endothelial dysfunction in GTP-cyclohydrolase I-deficient hph1 mice. J Cardiovasc Pharmacol 64:514-21

Showing the most recent 10 out of 16 publications